• MJHLS Brand Logo

© 2026 MJH Life Sciences™ and The Center for Biosimilars - Biosimilars, Health Economics & Insights. All rights reserved.

Eculizumab Biosimilar Shows Durable Benefit in Long-Term aHUS

July 29, 2026

A 50-patient study found sustained platelet recovery and low thrombotic microangiopathy rates through 52 weeks of biosimilar therapy, with favorable safety.

Biosimilar Bills Gain Steam in Congress, But Key Reforms Still Wait

July 23, 2026

Aflibercept Biosimilar SB15 Shows Real-World Efficacy Across Retinal Diseases

July 22, 2026

Biosimilar Ranibizumab Performs on Par With Innovator Drug Across Retinal Diseases

July 21, 2026

Real-World Natalizumab Biosimilar Switch Reduced Treatment Satisfaction Despite Stable Outcomes

July 20, 2026

Featured Content

Romosozumab Biosimilar Matches Reference in Functional Testing Despite Disulfide Differences

July 16th 2026

By Brooke McCormick

Article

A romosozumab biosimilar showed comparable sclerostin binding and bone-signaling potency to the reference product despite disulfide isoform differences.

FDA Accepts Sandoz Generic Tirzepatide Applications Amid Biosimilar Development Gap

July 13th 2026

By Skylar Jeremias

Article

Sandoz moves toward US generic tirzepatide autoinjectors as FDA reviews ANDAs, signaling future GLP‑1 access amid patent and biosimilar gaps.

Anti-VEGF Biosimilars Match Reference Drug in Indian Retinal Disease Care

July 9th 2026

By Skylar Jeremias

Article

Biosimilar anti-VEGF agents matched the reference ranibizumab in vision outcomes and safety across retinal diseases in India, at a lower cost.

Rituximab Biosimilar Reached 75% Remission, Matched Innovator in Membranous Nephropathy

July 8th 2026

By Skylar Jeremias

Article

Real-world data shows rituximab biosimilars for membranous nephropathy match remission rates, cut costs, and expand treatment options.

Biosimilar ABP 654 Maintains Efficacy, Safety After Repeated Switching From Ustekinumab

July 7th 2026

By Skylar Jeremias

Article

Trial data show switching between ABP 654 and reference ustekinumab maintains similar psoriasis control, safety, and immunogenicity, supporting FDA interchangeability confidence.

Biosimilar Denosumab Matches Reference Drug for Bone Density in Chinese Women

July 6th 2026

By Skylar Jeremias

Article

Phase 3 data show denosumab biosimilar KN012 matches Prolia for BMD gains and safety, potentially expanding affordable osteoporosis care.

Biosimilar Makers Push Forward on Regulatory and Commercial Fronts

July 2nd 2026

By Skylar Jeremias

Article

FDA expands Tofidence uses, Teva launches Eylea biosimilar in Europe, and Alvotech’s Entyvio rival enters FDA review—boosting access.

Positioning Biosimilar Ustekinumab Early Reduces Burden on Spain's National Health System

June 26th 2026

By Skylar Jeremias

Article

Early use of ustekinumab biosimilars in Spain shows cost-effective Crohn disease care, boosting QALYs and cutting NHS spend—insights for Europe.

Global Biosimilar Rules Diverge Across WHO Regions, Limiting Patient Access

June 24th 2026

By Skylar Jeremias

Article

Global review reveals uneven biosimilar rules on waivers, interchangeability, and safety tracking—barriers to cheaper biologics and approvals.

Low Biosimilar Awareness in MS Patients Points to Critical Gap in Nurse-Led Education

June 18th 2026

By Skylar Jeremias

Article

Italian study finds most MS patients start biosimilars unaware, exposing education gaps and highlighting MS nurses as key to boosting trust and uptake.